Immunotherapy beyond progression in patients with advanced non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) represent a great breakthrough in the treatment of advanced non-small cell lung cancer (aNSCLC). However, whether immunotherapy beyond progression (IBP) is effective for aNSCLC has yet to be established. Therefore, a retrospective clinical study was co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xiangwei, Zhang, Zhibo, Zhang, Sujie, Yuan, Fang, Zhang, Fan, Yan, Xiang, Han, Xiao, Ma, Junxun, Wang, Lijie, Tao, Haitao, Li, Xiaoyan, Zhi, Xiaoyu, Huang, Zhiyue, Hofman, Paul, Prelaj, Arsela, Banna, Giuseppe Luigi, Mutti, Luciano, Hu, Yi, Wang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815351/
https://www.ncbi.nlm.nih.gov/pubmed/33489801
http://dx.doi.org/10.21037/tlcr-20-1252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815351/
https://www.ncbi.nlm.nih.gov/pubmed/33489801
http://dx.doi.org/10.21037/tlcr-20-1252

Ejemplares similares